Estrogen receptor alpha (ERα) and Estrogen receptor beta (ERβ) (ERα and ERβ)

Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) are ligand-activated nuclear transcription factors in the steroid hormone receptor superfamily, encoded by the ESR1 and ESR2 genes, respectively[1][2][3][4][7][9]. These receptors mediate the biological effects of estrogens, such as estradiol, in multiple tissues, including reproductive organs, bone, brain, immune and cardiovascular systems. Both ERα and ERβ share similar modular domain structures that include DNA-binding and ligand-binding domains, though their sequence homology and functional properties differ, leading to subtype-specific tissue distribution and physiological roles[1][2][3][4][7]. ERα is predominantly associated with the regulation of cell proliferation in mammary gland and uterus, while ERβ generally inhibits proliferation and exerts anti-proliferative effects, such as in the prostate and immune tissues[3][4]. The balance of ERα and ERβ activity plays a crucial role in development, tissue homeostasis, disease progression (e.g., cancer and osteoporosis), and response to hormone therapy[3][9]. Both receptors are therapeutic targets for drugs including SERMs (e.g., tamoxifen, raloxifene), SERDs (e.g., fulvestrant), and selective agonists or antagonists directed at each receptor subtype, and their expression is used clinically to guide hormone therapy selection in cancer management[3][5][7].

Other names

Estrogen receptor 1 (ERα: ESR1 gene)Estrogen receptor 2 (ERβ: ESR2 gene)Nuclear receptor subfamily 3 group A member 1 (NR3A1, ERα)Nuclear receptor subfamily 3 group A member 2 (NR3A2, ERβ)Estrogen nuclear receptor alpha/beta

Agonists: Bind and activate ERα and/or ERβ, modulating transcription of estrogen-responsive genes. Antagonists/SERMs: Bind to ERα and/or ERβ and either block or modulate estrogenic transcriptional activity in a tissue-selective manner. SERDs: Promote degradation of the receptor, leading to reduced transcriptional activation. Inhibitors: Block binding of estrogen to the receptor, preventing downstream signaling.